Already facing competition from Sandoz, Amgen’s Neupogen white blood cell stimulator faces another cut-price near-copy after the FDA approved Pfizer’s biosimilar, Nivestym.
Amgen has failed in a legal attempt to block the sale of a biosimilar version of its white blood cell stimulator Neupogen developed by Novartis' Sandoz subsidiary. The biosimilar – called Zarxio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback